Journals / Annals of Medical Research / 2019 / Cilt: 26 - Sayı: 9

Evaluation of relationship between cytokine and chemokine levels measured by using multiplex laboratory method before and after treatment and clinical course and treatment response in rheumathoid arthritis patients receiving TNF-α blocker therapy

Pages
2053–2059
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The increase of mean hemoglobin (Hgb)levels between 0 and 6 months were statistically meaningful (both p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The laboratory findings are non-specific in Rheumatoid arthritis (RA).
📊
Key Findings & Data:We have based our study on this idea and chose cytokinesand chemokine to evaluate ; we then tried to establish a relationship between the progress of the disease and the levels of thesemolecules before and 3-6 months after the TNF-α blocker treatment.Material and Methods: A total of 34 RA patients (28 females, 6 males) who were diagnosed with RA and received TNF-α blockertherapy were included in the study.Blood samples were drawn from the patients before the TNF-α treatment began and then in thefollowing 3rd and 6th months of the treatment.Results: The mean age of the study group is 49.15±11.03. the mean disease period is 9.77±6.29 years and the mean treatment periodis 6.88±4.33 years. 84.6% (n=22) of the study group is female and 15.4% (n=4) is male.Patients with good treatment response toTNF-α blocker treatment were younger than the patients with medium treatment response.
💡
Conclusion & Impact:The increase of mean hemoglobin (Hgb)levels between 0 and 6 months were statistically meaningful (both p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The laboratory findings are non-specific in Rheumatoid arthritis (RA). We have based our study on this idea and chose cytokinesand chemokine to evaluate ; we then tried to establish a relationship between the progress of the disease and the levels of thesemolecules before and 3-6 months after the TNF-α blocker treatment.Material and Methods: A total of 34 RA patients (28 females, 6 males) who were diagnosed with RA and received TNF-α blockertherapy were included in the study.Blood samples were drawn from the patients before the TNF-α treatment began and then in thefollowing 3rd and 6th months of the treatment.Results: The mean age of the study group is 49.15±11.03. the mean disease period is 9.77±6.29 years and the mean treatment periodis 6.88±4.33 years. 84.6% (n=22) of the study group is female and 15.4% (n=4) is male.Patients with good treatment response toTNF-α blocker treatment were younger than the patients with medium treatment response. The increase of mean hemoglobin (Hgb)levels between 0 and 6 months were statistically meaningful (both p

🔖

Cite This Article

ERDEN, A. S., BULUR, A., İNANC, N. (2022). Evaluation of relationship between cytokine and chemokine levels measured by using multiplex laboratory method before and after treatment and clinical course and treatment response in rheumathoid arthritis patients receiving TNF-α blocker therapy. Annals of Medical Research, Cilt: 26 - Sayı: 9, 2053–2059. https://ajindex.com/articles/446718

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. McCarty DJ: Clinical picture of rheumatoid arthritis.In: Arthritis and allied conditions. McCarty DJ. (Eds). Lea and Febiger pp 781-809, 1993
  2. Guidelines for the Management of Rheumatoid Arthritis 2002 Update American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines, Arthritis Rheum 2002;46:328–46
  3. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996;39:723-31
  4. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Rheum 1996;39:1791-801
  5. Harris ED Jr. Rheumatoid arthritis: pathophysiology and implication for therapy. N Engl J Med 1990;322:1277–89
  6. Rheumatoid Arthritis: Diagnosis and Management, Arthritis Rheumatism 1988;31:315–24. 7. 2010 Rheumatoid Arthritis Classification Criteria An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative, Arthritis &Rheumatism. 2010;62:2569–81
  7. Hamuryudan V. İ.Ü.Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri, Türkiyede sık karşılaşılan hastalıklar dizisi, Enfeksiyon Hastalıkları, Romatizmal Hastalıklar, Afetlerde Ezilme Yaralanmaları Sempozyum Dizisi 2007 55; 69-86
  8. Hamuryudan V. İ.U.Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Romatolojik Hastalıklar, Sempozyum Dizisi No:34, Nisan 2003; s. 19-29, Romatoid Artrit
  9. Epidemiology of rheumatoid arthritis, S Akar, N Akkoç, Turkiye Klinikleri, J Int Med Sci 2006
  10. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol Rev 1981;3:27- 44
  11. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358:903-11
  12. O’Dell JR. ED, Rheumatoid arthritis. Rheum Dis Clinics North Ame.Philadelphia: Saunders WB Company, May 2001
  13. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713–22
  14. Saxne T Palladino MA Heinegard D et al. Detection of tumor necrosis factor alfa but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988;31:1041-5
  15. Sewell KL Trentham DE. Pathogenesis of rheumatoid arthritis. Lancet 1993;341:283-90
  16. Macías I1, García-Pérez S, Ruiz-Tudela M, et al. Modification o